Chemical Property of Dronedarone
Chemical Property:
- Vapor Pressure:1.47E-18mmHg at 25°C
- Melting Point:65.3°
- Refractive Index:1.563
- Boiling Point:683.9 °C at 760 mmHg
- PKA:7.40±0.30(Predicted)
- Flash Point:367.4 °C
- PSA：97.23000
- Density:1.143 g/cm3
- LogP:8.20280
- Storage Temp.:2-8°C
- Solubility.:≥27.84 mg/mL in DMSO; insoluble in H2O; ≥49.8 mg/mL in EtOH
- XLogP3:7.2
- Hydrogen Bond Donor Count:1
- Hydrogen Bond Acceptor Count:7
- Rotatable Bond Count:18
- Exact Mass:556.29709368
- Heavy Atom Count:39
- Complexity:800
- Purity/Quality:
-
97% *data from raw suppliers
Dronedarone-d6HCl *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Total 1 MSDS from other Authors
Useful:
- Drug Classes:Antiarrhythmic Agents
- Canonical SMILES:CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC
- Recent ClinicalTrials:Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation
- Recent EU Clinical Trials:First-line cryoablation for early treatment of Persistent Atrial Fibrillation – a randomized study comparing early trigger isolation using the Cryoballoon versus antiarrhythmic medication.
-
Description
AF is the most common form of sustained cardiac arrhythmia, with
an increasing prevalence in the aging population. AF accounts for
34.5% of arrhythmia-related hospital admissions in the United States.
The most significant consequences of AF include congestive heart failure, a 5-fold increased risk of stroke, and increased rate of mortality.
Although a 90% conversion rate from AF to normal sinus rhythm (NSR)
can be achieved with electrical cardioversion, up to 70% of these
patients require additional therapy with antiarrhythmic drugs in order
to maintain NSR.
Dronedarone, a close
analog of amiodarone, is structurally modified to provide improved
safety and pharmacokinetic profile. With the introduction of a sulfonamide group, dronedarone is less lipophilic, has lower tissue accumulation, and has a much shorter serum half-life (～24 h) compared with
amiodarone. Additionally, dronedarone lacks the iodine moieties that
are responsible for thyroid dysfunctions associated with amiodarone.
Dronedarone is specifically indicated to reduce the risk of cardiovascular hospitalization in patients with paroxysmal or persistent AF or AFL,
with a recent episode of AF/AFL and associated cardiovascular risk
factors, who are in sinus rhythm or who will be cardioverted. Similar to
amiodarone, dronedarone is a potent blocker of multiple ion currents
(including the rapidly activating delayed-rectifier potassium current,
the slowly activating delayed-rectifier potassium current, the inward rectifier potassium current, the acetylcholine-activated potassium current, peak sodium current, and L-type calcium current) and exhibits
antiadrenergic effects. Overall, dronedarone was well tolerated. The
most common side effects were gastrointestinal in nature and
included nausea, vomiting, and diarrhea.
-
Clinical Use
Anti-arrhythmic:Maintenance of sinus rhythm after successful
cardioversion in adult clinically stable patients with
paroxysmal or persistent atrial fibrillation
-
Drug interactions
Potentially hazardous interactions with other drugsAnti-arrhythmics: increased risk of myocardial
depression with other anti-arrhythmics; increased
risk of ventricular arrhythmias with amiodarone or
disopyramide - avoid. Antibacterials: increased risk of ventricular
arrhythmias with clarithromycin, telithromycin and
erythromycin; concentration reduced by rifampicin
- avoidAnticoagulants: increased anti-coagulant effect with
coumarins and phenindione; increased dabigatran
concentration - avoid; avoid with rivaroxaban;
concentration of edoxaban increased - reduce dose
of edoxaban.Antidepressants: concentration possibly reduced by
St John’s wort - avoid; increased risk of ventricular
arrhythmias with tricyclic antidepressants,
citalopram and escitalopram - avoid.Antiepileptics: concentration possibly reduced
by fosphenytoin, phenytoin, carbamazepine,
phenobarbital and primidone - avoid.Antifungals: concentration increased by ketoconazole
- avoid; avoid with itraconazole, posaconazole and
voriconazole.Antipsychotics: increased risk of ventricular
arrhythmias with antipsychotics that prolong the QT
interval; increased risk of ventricular arrhythmias
with phenothiazines - avoid.Antivirals: avoid with ritonavir; increased risk of
ventricular arrhythmias with saquinavir - avoid.Beta-blockers: increased risk of myocardial
depression; concentration of metoprolol and
propranolol possibly increased; increased risk of
ventricular arrhythmias with sotalol - avoid.Calcium channel blockers: concentration increased
by nifedipine; increased risk of bradycardia and
myocardial depression with diltiazem and verapamil.Cytotoxics: possibly increases bosutinib
concentration - avoid or consider reducing bosutinib
dose; possibly increases ibrutinib concentration -
reduce ibrutinib doseDigoxin: increased concentration (halve digoxin
maintenance dose).Fingolimod: possibly increased risk of bradycardia.Grapefruit juice: concentration of dronedarone
increased - avoid.Lipid-lowering drugs: concentration of atorvastatin
and rosuvastatin possibly increased; increased risk of myopathy with simvastatin; concentration of
lomitapide possibly increased - avoid.Tacrolimus: manufacturer advises use with caution.
